CYP2C9 inhibitor
- Inhibits CYP2C9
- CYP2C9 substrate exposure can rise
- Effect is greatest for sensitive substrates
- Toxicity risk rises with narrow-index victims
- Inhibition often begins faster than induction
- Warfarin/phenytoin/NSAIDs are classic substrates.
Interaction at a glance
Magnitude / time course
- Inhibits CYP2C9
- CYP2C9 substrate exposure can rise
Mechanism
- Effect is greatest for sensitive substrates
- Inhibition often begins faster than induction
- Warfarin/phenytoin/NSAIDs are classic substrates.
Clinical consequence
- Toxicity risk rises with narrow-index victims
Self-check
- What is the main clinical risk of CYP2C9 inhibitor?
Toxicity risk rises with narrow-index victims.
- Which enzyme or transporter is central to the CYP2C9 inhibitor interaction?
CYP2C9.
Drugs in this interaction (3)
All interaction examples · Open the interactive console ↗
